Barclays analyst Peter Lawson lowered the firm’s price target on Adaptimmune (ADAP) to 46c from $1 and keeps an Underweight rating on the shares. The company’s Q1 product revenue was roughly in line with consensus but it evaluated strategic options ongoing to address its constrained capital position, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Therapeutics Reports Q1 2025 Earnings
- ADAP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Adaptimmune Therapeutics CFO Departure Terms Revised
- Adaptimmune downgraded to Hold from Buy at JonesResearch
- Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue